EA
CRVS icon

Emerald Acquisition’s Corvus Pharmaceuticals CRVS Stock Holding History

Emerald Acquisition’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$392K Buy
23,859
+2,244
+10% +$32.3K ﹤0.01% 2524
2016
Q2 		$308K Buy
+21,615
New +$292K ﹤0.01% 2634

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Emerald Acquisition's CRVS Position: Q3 2016 in Review

Emerald Acquisition increased its Corvus Pharmaceuticals (CRVS) stake by 10% in Q3 2016, buying an estimated $32.3K and bringing the position to 23,859 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #2524.

Emerald Acquisition first reported a position in CRVS in Q2 2016 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold CRVS as of Q3 2016.

  • Emerald Acquisition held 23,859 shares of Corvus Pharmaceuticals worth $392K as of Q3 2016.
  • Emerald Acquisition bought 2,244 Corvus Pharmaceuticals shares in Q3 2016, an estimated $32.3K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2524 holding.
  • Emerald Acquisition first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.